SGMT Sagimet Biosciences
- 4.620
- -0.130-2.74%
- 4.650
- +0.030+0.65%
Sagimet Biosciences News
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Stifel cut
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibro
Sagimet Biosciences Is Maintained at Buy by Goldman Sachs
Sagimet Biosciences Is Maintained at Buy by Goldman Sachs
Express News | Goldman Sachs Maintains Buy on Sagimet Biosciences, Lowers Price Target to $23
Express News | HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
Promising Phase 2b Results Propel Sagimet Biosciences' Denifanstat Towards Pivotal Phase 3 Trial
Sagimet Biosciences: Strong Buy Rating on Robust Financials and Promising NASH Treatment Trials
Sagimet Biosciences: A Strong Buy on Robust Financials and Unique NASH Treatment Potential
Express News | Sagimet Biosciences Inc - End-of-Phase 2 Meeting With U.S. Food and Drug Administration (FDA) Expected in Q2 of 2024
Sagimet Biosciences 1Q Research and Development Expense $5.3M >SGMT
Sagimet Biosciences 1Q Research and Development Expense $5.3M >SGMT
Express News | Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Express News | Sagimet Biosciences Q1 Net Income USD -6.6 Million
Sagimet Biosciences | 10-Q: Quarterly report
Express News | Sagimet Announces Oral Presentation of Data From the Phase 2B Fascinate-2 Study of Denifanstat in Mash at Easl International Liver Congress 2024
Sagimet Biosciences Gets New Finance Head
Express News | Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
NOVA, STI and SGMT Are Among Premarket Gainers
Express News | Sagimet Biosciences Shares Are Trading Higher After HC Wainwright & Co. Initiated Coverage on the Stock With a Buy Rating and Announced a $32 Price Target
Sagimet Biosciences Initiated at Buy by HC Wainwright & Co.
Sagimet Biosciences Initiated at Buy by HC Wainwright & Co.
Express News | Sagimet Biosciences Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $32
Analysis
Price Target
No Data
